Advertisement

Advertisement

Advertisement

Advertisement

Other CancersCetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)Platinum (Cisplatin or Carboplatin) + 5-FUCompletedAustriaBelgiumCzech RepublicFranceGermanyHungaryItalyNetherlandsPolandPortugalRussian FederationSlovakiaSpainSwedenSwitzerlandUkraineUnited Kingdom10NCT00122460Phase 3
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy

No Results Found

The posts you requested could not be found. Try changing your module settings or create some new posts.

SELECT ONCOLOGY JOURNAL ARTICLES

Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer

Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer

Background Only a subset of patients with gastric cancer experience long-term benefits from immune checkpoint inhibitors (ICIs). Currently, there is a deficiency in precise predictive biomarkers for ICI efficacy. The aim of this study was to …

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Background Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies. If CAR-T cell therapy for non-hematological …

Colorectal cancer-specific IFN{beta} delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy

Colorectal cancer-specific IFN{beta} delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy

Background Cancer-intrinsic type I interferon (IFN-I) production triggered by radiotherapy (RT) is mainly dependent on cytosolic double-stranded DNA (dsDNA)-mediated cGAS/STING signaling and increases cancer immunogenicity and enhances the antitumor immune response to increase therapeutic efficacy. However, …